Investigation Report on China’s Pregabalin Market 2021-2025

$2,600$3,900

In 2020, the sales value of Pregabalin in the Chinese market is approximately CNY186 million. The CAGR in sales value of Pregabalin from 2016 to 2020 is 40.55%.

Clear

Description

China’s Pregabalin market size increased year by year from 2016 to 2020, according to CRI’s research. Among them, the growth in sales value in 2019 was the most obvious. The sales value of Pregabalin reached CNY143 million in 2019, with an annual growth rate of 57.19%. The main reason is that Pregabalin was approved for new indications in China from 2018 to 2019, and the NMPA lifted the restriction on Pregabalin medical insurance indications in 2019, which led to a substantial increase in its sales volume and sales value.

In 2020, the sales value of Pregabalin in the Chinese market is approximately CNY186 million. The CAGR in sales value of Pregabalin from 2016 to 2020 is 40.55%.

Pregabalin is an ion channel modulator used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. Its product, LYRICA was originally developed by Pfizer Ltd. LYRICA was launched in China in 2010 and was approved for the treatment of post-herpetic neuralgia. In 2018, it was approved for fibromyalgia indication. Subsequently, some generic drugs of Pregabalin were launched in China one after another.

In 2019, Pregabalin (trade name: Laireike) produced by Chongqing Saiwei Pharmaceutical was approved for the treatment of adult partial epilepsy, adding a new indication for Pregabalin in the Chinese market. By 2020, Pregabalin has been included in China’s Class B medical insurance, and there are three manufactures in the Chinese market, of which Pfizer Ltd is the main manufacture.

CRI expects that with the addition of new companies, the sales volume and market scale of Pregabalin in the Chinese market will continue to expand from 2021 to 2025. According to CRI’s market research, by the first half of 2021, there are more than 20 companies in China that are applying for Pregabalin generic drugs, including Jiangsu Hengrui Pharmaceutical Co., Ltd., Xuzhou Enhua Pharmaceutical Co., Ltd., and Sichuan Kelun Pharmaceutical Co., Ltd. In addition, China has approved the marketing of 3 indications of Pregabalin, and a total of 4 indications have been approved for marketing globally. Therefore, the number of indications of Pregabalin in China is likely to increase, and sales value and sales volume will increase in the future.

 

Topics Covered in Investigation Report on China’s Pregabalin Market 2021-2025

  • -The impact of COVID-19 on China’s Pregabalin market
  • – Sales value of China’s Pregabalin 2016-2020
  • – Competitive landscape of China’s Pregabalin market
  • – Prices of Pregabalin in China
  • – Prices of Pregabalin in China by regions and manufacturers
  • – Analysis on factors affecting the development of China’s Pregabalin market
  • – Prospect of China’s Pregabalin market from 2021 to 2025

Investigation Report on Chinese Pregabalin Market, 2020-2024

Additional information

Publisher

Date Published

Pages

Charts

Format

Table of Contents

1 Relevant Concepts of Pregabalin

  • 1.1 Indications for Pregabalin
  • 1.2 Development of Pregabalin in China
  • 1.3 Governmental Approval of Pregabalin in China
  • 1.4 The Impact of COVID-19 on Pregabalin sales in China

 

2 Sales of Pregabalin in China, 2016-2020

  • 2.1 Sales Value of Pregabalin
  • 2.1.1 Overall Sales Value
  • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Pregabalin
  • 2.2.1 Overall Sales Volume
  • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Pregabalin by Dosage Form in China, 2016-2020
  • 2.3.1 Capsules
  • 2.3.2 Analysis of Other Dosage Forms

 

3 Analysis of Major Pregabalin Manufacturers in China in 2020

  • 3.1 Analysis of Market Share of Major Pregabalin Manufacturers
  • 3.1.1 Investigation on Market Share by Sales Value
  • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Pfizer Ltd
  • 3.2.1 Enterprise Profile
  • 3.2.2 Sales of LYRICA (Pfizer Ltd’s Pregabalin) in China
  • 3.3 Chongqing Saiwei Pharmaceutical Co., Ltd.
  • 3.3.1 Enterprise Profile
  • 3.3.2 Sales of Laireike (Chongqing Saiwei Pharmaceutical Co., Ltd.’s Pregabalin) in China
  • 3.4 Qilu Pharmaceutical (Hainan) Co., Ltd.
  • 3.4.1 Enterprise Profile
  • 3.4.2 Sales of Xisiping (Qilu Pharmaceutical (Hainan) Co., Ltd.’s Pregabalin) in China

 

4 Prices of Pregabalin for Different Manufacturers in China, 2020-2021

  • 4.1 Pfizer Ltd (LYRICA)
  • 4.2 Chongqing Saiwei Pharmaceutical Co., Ltd. (Laireike)
  • 4.3 Qilu Pharmaceutical (Hainan) Co., Ltd. (Xisiping)

 

5 Prospect of Chinese Pregabalin drug Market, 2021-2025

  • 5.1 Influential Factors of Chinese Pregabalin Market Development
  • 5.1.1 The Impact of COVID-19 on Chinese Pregabalin Market
  • 5.1.2 Market Drivers and Opportunities
  • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

 

List of Charts

  • Chart Patent Information About Pregabalin Capsules Registration in China
  • Chart Sales Value of Pregabalin Capsules over the World
  • Chart Sales Value of Pregabalin Capsules in China, 2016-2020
  • Chart Sales Value of Pregabalin Capsules in China by Region, 2016-2020
  • Chart Sales Volume of Pregabalin Capsules in China, 2016-2020
  • Chart Sales Volume of Pregabalin Capsules in China by Region, 2016-2020
  • Chart Market Share by Sales Value of Top Pregabalin Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of LYRICA in China, 2016-2020
  • Chart Sales Value and Volume of Laireike in China, 2016-2020
  • Chart Sales Value and Volume of Xisiping in China, 2016-2020
  • Chart Referential Prices of LYRICA in China, 2020-2021
  • Chart Referential Prices of Laireike in China, 2020-2021
  • Chart Referential Prices of Xisiping in China, 2020-2021
  • Chart Forecast on Sales Value of Pregabalin in China, 2021-2025
  • Chart Forecast on Sales Volume of Pregabalin in China, 2021-2025